Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Curvebeam AI Ltd. ( (AU:CVB) ) just unveiled an announcement.
CurveBeam AI Limited announced an update regarding the settlement of a $6.5 million placement, where $5.6 million has been received, and the remaining $900,000 is pending due to an offshore transfer delay. The company plans to issue the shares in two tranches, with the first tranche settled and issued, and the second tranche pending receipt of funds. This placement is expected to support the company’s operations and enhance its market positioning in the medical imaging industry.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited (ASX: CVB) is a company that develops, manufactures, and sells specialized medical imaging CT scanners, combined with AI SaaS-based clinical assessment solutions. These products are designed to assist medical practitioners in managing musculoskeletal conditions. The company’s flagship product, HiRise™, offers both weight-bearing and traditional non-weight-bearing CT scans, providing advantages over traditional CT or MRI devices. CurveBeam AI operates with over 70 employees, with its corporate office and AI functions located in Melbourne, Australia, and its global operations headquarters in Hatfield, Pennsylvania, USA.
Average Trading Volume: 301,522
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$39.56M
For a thorough assessment of CVB stock, go to TipRanks’ Stock Analysis page.